For the use of Registered Medical Practitioner or a Hospital or a Laboratory only

Nimesulide Tablets


NIMULID (Nimesulide) is described chemically as N-(4-Nitro-2-phenoxyphenyl) methanesulphonamide. It has the following structure:

Nimesulide is a yellowish crystalline powder. It is practically insoluble in water, freely soluble in acetone and slightly soluble in ethanol. The empirical formula for Nimesulide is C13 H12N2O5S, and the molecular weight is 308.311.

Each tablet of Nimulid for oral administration contains 100mg of Nimesulide BP and the following inactive ingredients: Lactose, Croscarmellose Sodium, Colloidal Silicon Dioxide, Maize Starch, Povidone, Polysorbate-80 and Magnesium Stearate.

Nimulid tablet is pale yellow, coloured, round, biconvex, uncoated tablet with imprints of "NIMULID" on one side and "picture of Logo" on the other.

CLINICAL Pharmacology

Mechanism of Action Nimesulide is a sulfonanilide non-steroidal anti-inflammatory drug whose anti-inflammatory analgesic and antipyretic activities have been demonstrated in several widely used animal experimental models2. At the recommended dose of 100 mg b.i.d., it is as effective an analgesic and anti-inflammatory agent as classical NSAIDs, and a well-tolerated drug with fewer side effects as evidenced by a number of controlled and non-controlled comparative trials3. Nimesulide is a unique NSAID, not only due to its chemical structure but also because of its specific affinity to inhibit Cyclooxygenase-2 thus exerting milder effects on the gastrointestinal mucosa.

Nimesulide appears to exert its therapeutics effects through a variety of mechanisms viz4:

  • Selective Cyclooxygenase-2 inhibitor
  • Reduced generation of superoxide anions by stimulated polymorphonuclear leucocytes
  • Inhibition of platelet aggregation factor synthesis by activated cells
  • Scavenger of inactivation of alpha1-protease inhibitor
  • Inhibition of histamine release
  • Inhibition of protein kinase C through inhibition of phosphodiesterase type IV
  • Reduced degradation of cartilage matrix through inhibition of metalloprotease synthesis
  • Potent inhibition of induced platelet aggregation
  • Prevention of bradykinin/cytokine induced hyperalgesia of nerves (inhibiting release of TNF- alpha)


Absorption Nimesulide is fairly rapidly absorbed from the gastrointestinal tract. After oral administration of a 100mg dose to healthy fasting volunteers, mean maximum plasma concentration (Cmax) values of 2.86 to 4.58 mg/L were achieved within 1.22 to 3.83 hours (Tmax). After oral administration of a 200mg dose in tablet form, urinary recovery was approximately 80% and faecal recovery about 20% over a 3-day period. Thus by mass balance, it can be deduced that at least 80% of the administered dose was absorbed by the gastrointestinal tract. Given that Nimesulide and/or its metabolites may also be excreted in the bile, the extent of Nimesulide absorption after oral administration is likely to be greater than 80%. After administration of Nimesulide 100mg to healthy fasting volunteers, the area under the plasma concentration-time curve (AUC) values ranged from 17.3 to 30.9mg/L.h. Appreciable Nimesulide concentrations of 0.12 to 1.03mg/L were still measurable 12 hours after administration, the time at which successive dose is given in the recommended dose regimen.

Nimesulide is absorbed at a similar rate and to the same extent whether administered in tablet, suspension or granular form5.

Food effects

Oral administration of Nimesulide 100mg tablets after a standard breakfast resulted in a Cmax value approximately 20% lower (3.02mg/L) than under fasting conditions. However, neither tmax (1.75h) nor AUC (15.9mg/L.h) values were significantly modified by food intake. In contrast, Ambrosioni (1986) reported that when the drug was administered in the presence of food, Nimesulide plasma concentrations were 2 to 4 fold higher than under fasting conditions, suggesting that the drug was better absorbed after meals.


The volume of distribution in the post distribution phase for Nimesulide ranges from 0.19 to 0.39 L/kg, indicating that the drug is principally distributed in the extra cellular fluid compartment. Over a drug concentration range of 0.5 to 10 mg/L, the unbound fraction for Nimesulide varied from 0.007 to 0.04, which was indicative of its extensive plasma protein binding.

Nimesulide is almost exclusively metabolized and cleared by the liver. Metabolic biotransformation of Nimesulide in the liver can occur at both the phenoxy ring moiety and the aromatic nitro group. The major oxidative metabolite found in the plasma is para-hydroxy nimesulide in both free and conjugated forms and this metabolite also appears to contribute to the anti-inflammatory activity of the compound6.


After oral administration of Nimesulide 100 mg, the apparent mean elimination half-life (t½β) varied from 1.96 to 4.75 hours. Nimesulide is mainly eliminated by the renal route. Nimesulide total plasma clearance varied from 35.2 to 90.9 ml/h/kg and was almost exclusively attributed to metabolic clearance. Para hydroxy Nimesulide has an elimination half-life of 2.89 to 4.78 hours (t½β).

Special populations


The pharmacokinetic profile of Nimesulide and its para-hydroxy metabolite was similar in the elderly and young healthy volunteers and suggest that no Nimesulide dosage adjustment is necessary in patients less than 80 years of age7.


Gender does not appear to substantially affect the rate or the extent of Nimesulide absorption, distribution and elimination. It is noteworthy, however, that the mean peak plasma concentration, total plasma clearance and volume of distribution in the post-distributive phase were higher in females than in males.


Nimesulide seems to be rapidly and extensively absorbed in children. There was a 50% increase in Cmax and AUC values in children when compared with healthy adults, while the dose in children expressed on a bodyweight basis was only 20% greater (1.82 vs 1.54mg/kg). Furthermore, the terminal elimination half-life (t 1/β) of Nimesulide was shorter in children (2.36h) than in adults (3.02h) suggesting faster elimination in pediatric subjects.

Renal Insufficiency

The pharmacokinetic profile of Nimesulide in volunteers with moderate renal impairment was assessed in two non-blind studies. In the first study, a single dose of 100mg of Nimesulide was administered to 10 patients between 18 to 65 years of age. The apparent total clearance (Cltot) for Nimesulide was significantly lower (2.9 vs 4.8L/h) and the terminal elimination half-life for hydroxy nimesulide was significantly longer (6.05 vs 4.02h) in renally impaired patients.

The second investigation assessed the pharmacokinetic profile of repeat doses of Nimesulide in 10 patients between 49 to 69 years of age. Analysis of data showed that the AUC0-alpha for hydroxy nimesulide was slightly greater (19.7 vs15.4mg/L.h) following repeat dose administration. The urinary clearance for hydroxy nimesulide at steady state was higher than that after the first dose (1.02L/h).

Results of these studies suggested that the pharmacokinetic profiles of Nimesulide and its hydroxy metabolites are not altered significantly in patients with moderate renal failure.

Drug Interactions

Extensively plasma protein bound drugs Due to the extensive plasma protein-binding Nimesulide may be displaced from the binding site by concurrent administration of fenofibrate, salicylic acid, valproic acid and tolbutamide. Moreover, Nimesulide may displace salicylic acid, methotrexate and furosemide from binding sites8.

Furosemide Nimesulide reduced the diuretic effect for concomitantly administered furosemide.

Digoxin Concomitant administration of Nimesulide and Digoxin showed no effect on serum Digoxin concentrations at steady state.

Warfarin Nimesulide does not appear to interact with Warfarin, in clinical practice; although interaction with oral anticoagulants or other highly protein bound drugs cannot be ruled out.

Theophylline Nimesulide may cause enzymatic induction of Theophylline when administered concomitantly with it.

Antidiabetic agents

Nimesulide had no significant effect on fasting blood and glucose tolerance in patients treated with antidiabetic agents.

clinical studies

Liver disease A study describes of a 57 year old female patient with chronic lumbago, who died from the sequale of acute liver failure, reported to be induced by Nimesulide medication. Past medical history revealed that the patient had been taking Ibuprofen, Mefenamic acid, Paracetamol and Oxazepam for the past many years. Concomitant administration of these drugs might have predisposed the liver to toxic manifestation, which got aggravated on Nimesulide use. Hence caution is advised when using these drugs alongside Nimesulide9.

Concomitant medications A case, reports of a patient who developed fulminant liver failure on treatment with Nimesulide. Past history of the patient revealed that she was taking conjugated estrogens and sertraline since the last 10 and 5 years respectively. This previous exposure may have sensitized the patient to accelerated liver injury that got aggravated on Nimesulide use. Hence caution is advised on the use of sertraline and conjugated estrogens with Nimesulide10.

Of the hepatic ADRs reported to the WHO in relation to Nimesulide, two cases were compatible with Reye's syndrome. They were both fatal. But in the cases reported, all patients were concomitantly administered with Amoxycillin and Clavulanate. One cannot firmly exclude the role of Amoxycillin and Clavulanate in causing liver damage. Hence the use of such antibiotics alongside Nimesulide should be avoided11.

Indications and usage
Nimesulide is indicated in reducing pain, fever and inflammatory symptoms of:

  • Chronic arthritis (Osteoarthritis)
  • Respiratory tract infections
  • Otorhinolaryngological diseases
  • Soft tissues and oral cavity inflammation
  • Dysmenorrhoea
  • Phlebitis / thrombosis
  • Urogenital disease
  • Postoperative pain states
  • Sports injuries.


  • History of allergy to NSAIDs12
  • History of nasal polyps, angiodema and /or bronchospastic reactivity to any NSAID
  • Hypovolaemia/dehydration (>10% total body weight)
  • Peptic ulcer disease
  • Renal insufficiency
  • Hepatic insufficiency
  • Bleeding disorders
  • Concomitant administration of drugs known to interact with NSAIDs/Nimesulide such as anti-diabetics and anti-epileptics.
  • History of allergy to any of its components.


Gastrointestinal (GI) Effects- Risk of GI Ulceration, Bleeding and Perforation Serious gastrointestinal toxicity such as bleeding, ulceration, and perforation of the stomach, small intestine or large intestine, can occur at any time, with or without warning symptoms, in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs). Minor upper gastrointestinal problems, such as dyspepsia, are common and may also occur at any time during NSAID therapy. Therefore, physicians and patients should remain alert for ulceration and bleeding, even in the absence of previous GI tract symptoms. Patients should be informed about the signs and/or symptoms of serious GI toxicity and the steps to be taken if they occur.

NSAIDs should be prescribed with extreme caution in patients with a prior history of ulcer disease or gastrointestinal bleeding. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore special care should be taken in treating this population. To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.

Studies have shown that patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding and who use NSAIDs, have a greater than 10-fold higher risk for developing a GI bleed than patients with neither of these risk factors. In addition to a past history of ulcer disease, pharmaco-epidemiological studies have identified several other co-therapies or co-morbid conditions that may increase the risk for GI bleeding such as: treatment with oral corticosteroids, treatment with anticoagulants, longer duration of NSAID therapy, smoking, alcoholism, older age, and poor general health status.

The results of clinical trials suggest that Nimesulide is better tolerated than classical NSAIDs, especially in regards to gastrointestinal adverse reactions. Various studies have found that gastric mucosal damage by Nimesulide is either similar to placebo or better than reference compounds.13,14

Anaphylactoid Reactions

As with NSAIDs in general, anaphylactoid reactions have occurred in patients without known prior exposure to Nimesulide. In post-marketing experience, rare cases of anaphylactoid reactions and angioedema have been reported in patients receiving Nimesulide. Emergency help should be sought in cases where an anaphylactoid reaction occurs.

Advanced Renal Disease No safety information is available regarding the use of Nimesulide in patients with advanced kidney disease. Therefore, treatment with Nimesulide is not recommended in these patients. If Nimesulide therapy must be initiated, close monitoring of the patient's kidney function is advisable (see PRECAUTIONS, Renal Effects).

Pregnancy In late pregnancy Nimesulide should be avoided because it may cause neonatal as well as perinatal toxicity. Nimesulide use in pregnant women should only be done if the potential benefits overweigh the risks and under medical supervision.


Hepatic Effects

Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs, and notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure (some with fatal outcome) have been reported with NSAIDs as well as Nimesulide. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be monitored carefully for evidence of the development of a more severe hepatic reaction while on therapy with Nimulid. Use of Nimesulide is not recommended in patients with moderate or severe hepatic insufficiency. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), Nimesulide should be discontinued.

Renal Effects

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

Caution should be used when initiating treatment with Nimesulide in patients with considerable dehydration. Caution is also recommended in patients with pre-existing kidney disease, nephritic syndrome, chronic renal failure, congestive heart failure or diuretic induced sodium depletion.

Preexisting Asthma

Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm which can be fatal. Cross reactivity, including bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients. However, Nimesulide has demonstrated better tolerability when administered to patients with this form of aspirin sensitivity15,16.

Information for Patients Patients should promptly report signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, unexplained weight gain, or edema to their physicians.

Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.

Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction (see WARNINGS).

Laboratory Tests

Because serious hepatic toxicity can occur without warning symptoms, physicians should monitor for signs or symptoms of hepatic toxicity.

Adverse reactions

World wide, the majority of adverse reactions recorded affected the digestive system followed by the skin and the nervous system. Of the 17 ADR reports ascribed to Nimesulide as received by the national pharmacovigilance center of the WHO, 5 were of the skin and 4 of the liver. Others were peripheral oedema (2), stomatitis (2), paresthesia (1), thrombocytopaenic purpura (1), irritability (1) and headache / reduced visual activity (1). No adverse GI reactions have been reported. Of the hepatic ADR's reported; two cases were compatible with Reye's syndrome. Nimesulide may also cause acute hepatitis and an elevation in liver enzymes17.

Between the years 1985 and 2000, a total number of 192 hepatic ADRs were reported with Nimesulide. Out of these 81 were considered to be serious and 111 as non serious. Based on the mean treatment time of 2 weeks for acute treatment and 6 months for chronic treatment, the incidence of adverse effect was found to be 0.1 per 100,000 cases. For most other NSAIDs, the absolute risk is 1-4 per 100,000 cases18.

The adverse effect profile of Nimesulide in Indian population in children was similar to that reported for all age groups. The adverse effects reported in 4097 case report forms were gastrointestinal (3.1%), vomiting (1.34%), burning stomach / irritation in stomach (0.60%), abdominal pain (0.50%), diarrhoea (0.40%), nausea (0.17%), black stools (0.10%), hematemesis (0.02%), skin and mucous membrane (1.7%), itching / rash / urticaria (1.50%), cold and clammy skin (0.10%), stomatitis (0.04%), yellow discolouration (0.04%), dry red lips (0.02%), bleeding gums (0.02%), renal (0.3%), generalised edema (0.10%), hematuria (0.10%), reduced urine output (0.04%), burning micturition (0.04%), nephritis (0.02%), CNS (0.4%), drowsiness (0.12%), dizziness (0.10%), irritability (0.15%), heavy headedness (0.02%), others (1.3%), puffiness of face / eyelids (0.70%), hypothermia (0.31%), excessive sweating (0.17%), muscle pain (0.07%), chest pain (0.02%), joint swelling (0.02%), peripheral cyanosis (0.02%) and worsening (0.02%).Out of these only patients with hypothermia, hemetemesis and muscle pains required hospitalization, but all subsided after stopping the drug19.


No data is available on overdosage toxicity. In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive therapy, if required.

DOSAGE AND administration

The usual oral dosage of Nimesulide in adults is 100 to 200 mg twice daily.

Storage instructions

Store in a cool, dry and dark place.


Available in blister strips of 10x10's tablets.



  1. Kulkarni SK. On the safety of nimesulide, a preferential COX-2 inhibitor. Current science 2002; 83(12): 1442 _ 1443.
  2. Rabasseda X. Nimesulide: A selective cyclooxygenase-2 inhibitor anti-inflammatory drug. Drugs of Today 1996; 32(Suppl D): 1- 23.
  3. Famaey JP. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: An overview 1997; 46: 437-46.
  4. Tognella S. Nimesulide: New clinical opportunities 1993; 46 (Suppl 1) : 275-76.
  5. Bernareggi A. The pharmacokinetic profile of Nimesulide in healthy volunteers. Drugs 1993; 46(Supp 1): 64 - 72.
  6. Boelsterli UA. Mechanisms of NSAID-induced hepato-toxicity: Focus on Nimesulide. Drug Saf 2002; 25(9): 633-48.
  7. Olive G and Rey E. Effect of age and disease on the pharmacokinetics of Nimesulide. Drugs 1993; 46(Supp 1): 73 _ 78.
  8. Perucca E. Drug Interactions with Nimesulide. Drugs 1993; 46(Suppl 1): 79 _ 82.
  9. Merlani G, Fox M, Oehen HP, et al. Fatal hepatotoxicity secondary to Nimesulide. Eur J Clin Pharmacol 2001; 57(4): 321-26.
  10. McCormick PA, Kennedy, Curry M, et al. COX-2 inhibitor and fulminant hepatic failure. The Lancet 1999; 353: 40-41.
  11. National drug monitoring centres-drug safety issues. Adverse reaction newsletter 1999:2:6.
  12. Litalien C and Lacqz-Aigrain E. Risks and Benefits of non-steroidal anti-inflammatory drugs in children: Comparison with paracetamol. Pediatr Drugs 2001; 3(11): 817 _ 58.
  13. Rabasseda X. Safety profile of Nimesulide: ten years of clinical experience. Drugs of today 1997; 33 (Suppl 1): 1 _ 10.
  14. Warner TD. Introduction to Nimesulide: Beyond COX-2. Clin Exp Rheumatol 2001; 19 (Suppl 22): S1-S2.
  15. Sethi GR, Sharma S, Batra V et al. Double-blind, placebo-controlled study of the efficacy and tolerability of Nimesulide administered orally in acute bronchial asthma. American Journal of Therapeutics 2002; 9: 281 _ 287.
  16. Bianco S, Robuschi M, Petrigni G et al. Efficacy and tolerability of Nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993; 46 (Suppl 1): 115 _ 120.
  17. From the editor. Nimesulide adverse reactions reported to the CNF. Boletin de Farmacovigilancia 1998; 2(3-3rdQuarter): 1-2.
  18. Boelsterli UA. Nimesulide and hepatic adverse effects: roles of reactive metabolites and host factors. Int J Clin Pract Suppl 2002; 128:30-36.
  19. Srishyla MV, Sireesha K, Bhaduri J, et al. Letter to the editor. Indian Pediatrics 2002; 39: 310 _ 311.


Latest EMEA opinion on Nimesulide / NSAIDs